No evidence for increased cancer risk has been reported during an extended trial investigating the effects of neutral protamine Hagedorn (NPH) insulin and insulin glargine effects on the development of retinopathy [29] or in the meta-analysis of 31 insulin glargine studies [30]. Here, INS is linked to retinal disorder.